These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 20877357)

  • 1. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.
    Gerlinger M; Swanton C
    Br J Cancer; 2010 Oct; 103(8):1139-43. PubMed ID: 20877357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour heterogeneity and the evolution of polyclonal drug resistance.
    Burrell RA; Swanton C
    Mol Oncol; 2014 Sep; 8(6):1095-111. PubMed ID: 25087573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolutionary scalpels for dissecting tumor ecosystems.
    Rosenbloom DIS; Camara PG; Chu T; Rabadan R
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):69-83. PubMed ID: 27923679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
    Kim JY; Gatenby RA
    Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perturbation-Driven Entropy as a Source of Cancer Cell Heterogeneity.
    Nijman SMB
    Trends Cancer; 2020 Jun; 6(6):454-461. PubMed ID: 32460001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-tumour heterogeneity - going beyond genetics.
    Caiado F; Silva-Santos B; Norell H
    FEBS J; 2016 Jun; 283(12):2245-58. PubMed ID: 26945550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic heterogeneity and cancer drug resistance.
    Turner NC; Reis-Filho JS
    Lancet Oncol; 2012 Apr; 13(4):e178-85. PubMed ID: 22469128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again!
    Wooten DJ; Quaranta V
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):167-175. PubMed ID: 28396217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumor heterogeneity: evolution through space and time.
    Swanton C
    Cancer Res; 2012 Oct; 72(19):4875-82. PubMed ID: 23002210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population genetics perspective on the determinants of intra-tumor heterogeneity.
    Hu Z; Sun R; Curtis C
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):109-126. PubMed ID: 28274726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics.
    Lee AJ; Swanton C
    Biochem Pharmacol; 2012 Apr; 83(8):1013-20. PubMed ID: 22192819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
    Brioli A; Melchor L; Cavo M; Morgan GJ
    Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating evolutionary dynamics into cancer therapy.
    Gatenby RA; Brown JS
    Nat Rev Clin Oncol; 2020 Nov; 17(11):675-686. PubMed ID: 32699310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constraints in cancer evolution.
    Venkatesan S; Birkbak NJ; Swanton C
    Biochem Soc Trans; 2017 Feb; 45(1):1-13. PubMed ID: 28202655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catch my drift? Making sense of genomic intra-tumour heterogeneity.
    Sottoriva A; Barnes CP; Graham TA
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):95-100. PubMed ID: 28069394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.
    Venkatesan S; Swanton C; Taylor BS; Costello JF
    Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28289245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of memory in non-genetic inheritance and its impact on cancer treatment resistance.
    Cassidy T; Nichol D; Robertson-Tessi M; Craig M; Anderson ARA
    PLoS Comput Biol; 2021 Aug; 17(8):e1009348. PubMed ID: 34460809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).
    Smith CIE
    Semin Cancer Biol; 2017 Aug; 45():36-49. PubMed ID: 27865897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational implications of tumor heterogeneity.
    Jamal-Hanjani M; Quezada SA; Larkin J; Swanton C
    Clin Cancer Res; 2015 Mar; 21(6):1258-66. PubMed ID: 25770293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research.
    Aktipis CA; Kwan VS; Johnson KA; Neuberg SL; Maley CC
    PLoS One; 2011; 6(11):e26100. PubMed ID: 22125594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.